Belite Bio (NASDAQ:BLTE) Stock Falls 7.4% - Here's What Happened

Key Points

• Belite Bio shares fell 7.4% to about $157.34 in Friday trading, with volume down 81% versus its average.
• The FDA accepted the company’s tinlarebant application for priority review for Stargardt disease, though approval is not assured. Belite reported a quarterly net loss of $30.3 million, while its per-share loss was narrower than analysts expected.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $227.40. In contrast, company insiders sold 168,330 shares worth about $32 million over the past 90 days.

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report)'s stock price dropped 7.4% during trading on Friday. The stock traded as low as $157.65 and last traded at $157.3360. 35,932 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 190,025 shares. The stock had previously closed at $169.96.

Key Stories Impacting Belite Bio

Investors following BLTE have been watching these stories:

• Positive Sentiment: The FDA accepted Belite Bio’s NDA for tinlarebant for priority review, advancing the company’s effort to bring a treatment for Stargardt disease to market. Priority review may shorten the review timeline, though approval is not guaranteed. Belite Bio Q3 2026 earnings call highlights
• Positive Sentiment: Shares were reported to have moved above their 200-day moving average, a technical signal that some investors may view as improving momentum. Belite Bio share price breaks above 200-day moving average
• Negative Sentiment: The company recorded a quarterly net loss of $30.3 million. While losses are common for a development-stage biotech, continued spending and the need to fund operations remain risks as Belite works toward commercialization. Belite Bio reveals quarterly loss

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Canaccord Genuity Group assumed coverage on Belite Bio in a research report on Friday, September 4th. They set a "buy" rating and a $303.00 target price on the stock. Zacks Research cut Belite Bio from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 18th. Morgan Stanley raised their price objective on Belite Bio from $201.00 to $206.00 and gave the stock an "overweight" rating in a research note on Friday, August 14th. Mizuho raised their price objective on Belite Bio from $220.00 to $234.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 9th. Finally, Cantor Fitzgerald lifted their price objective on Belite Bio from $266.00 to $270.00 and gave the company an "overweight" rating in a research report on Wednesday, August 12th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $227.40.

Belite Bio Stock Down 5.0%

The company has a market capitalization of $6.50 billion, a PE ratio of -59.14 and a beta of -1.19. The company's 50 day moving average is $161.02 and its two-hundred day moving average is $160.25.

Belite Bio (NASDAQ:BLTE - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.19. Analysts forecast that Belite Bio, Inc. Sponsored ADR will post -3.08 EPS for the current year.

Insider Buying and Selling at Belite Bio

In other Belite Bio news, CEO Yu-Hsin Lin sold 74,435 shares of Belite Bio stock in a transaction on Friday, September 4th. The shares were sold at an average price of $187.71, for a total value of $13,972,193.85. Following the completion of the transaction, the chief executive officer directly owned 96,134 shares of the company's stock, valued at $18,045,313.14. This trade represents a 43.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Hao-Yuan Chuang sold 49,433 shares of the business's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $187.64, for a total value of $9,275,608.12. Following the sale, the chief financial officer directly owned 44,000 shares in the company, valued at $8,256,160. The trade was a 52.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 168,330 shares of company stock worth $31,969,118 over the last 90 days. 13.29% of the stock is owned by insiders.

Institutional Investors Weigh In On Belite Bio

Institutional investors and hedge funds have recently modified their holdings of the business. Candriam S.C.A. bought a new stake in Belite Bio during the 3rd quarter valued at about $10,711,000. Renaissance Technologies LLC bought a new position in Belite Bio in the first quarter worth about $8,291,000. Affinity Asset Advisors LLC lifted its position in Belite Bio by 225.0% during the first quarter. Affinity Asset Advisors LLC now owns 65,000 shares of the company's stock valued at $10,364,000 after acquiring an additional 45,000 shares during the last quarter. Alberta Investment Management Corp acquired a new stake in shares of Belite Bio in the 3rd quarter worth $4,076,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Belite Bio in the first quarter worth about $3,125,000. 0.53% of the stock is owned by institutional investors.

About Belite Bio

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.